Companies say they are working to update their products to comply with the Food and Drug Administration's decision Wednesday to ban the artificial food dye Red 3, after the agency said it was revoking ...
Red dye No. 3 has been permissible for use in food despite the Delaney Clause of the FDA’s Federal Food, Drug, and Cosmetic ...
The FDA wants front-of-package nutrition labels required on packaged foods. The labels would tell consumers if the product ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
The FDA removed Zepbound from its drug shortage list this week for the first time since its approval last year. However, some worry that the move could affect people who rely on cheaper generic ...
The Food and Drug Administration approved Eli Lilly’s weight-loss ... Lilly has struggled to make enough, leading the FDA to place it on a list of drugs in shortage and enabling compounding ...
FRIDAY, Dec. 27, 2024 (HealthDay News) -- Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce ... The FDA approval was based on data ...
The FDA approved Zepbound (tirzepatide ... “This is the first drug treatment for obstructive sleep apnea, and so that’s exciting, and it provides a good opportunity to help the care of ...
The approval of the once-daily injection (18 mg/3 mL), as an adjunct to diet ... the FDA's continued commitment to advancing patient access to safe, effective, and high-quality generic drug ...
The drug will be available in early January, and will be priced at parity with the list price of the IV version, Adam Lenkowsky, Bristol's chief commercialization officer, told Reuters ahead of the ...
The IV version of the drug has a list price of $7,635 per infusion for two weeks for the lower dose and $15,269 per infusion for four weeks for the higher 480-milligram dose. The approval was ...